Authorization

NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting

NewLink
Genetics Corporation (NASDAQ:NLNK) announced that updated Phase 1 dataA evaluating
indoximod plus standard-of-care chemotherapy for the treatment of adult
patients with newly diagnosed acute myeloid leukemia (AML) were
presented today by Ashkan Emadi, MD, PhD, Professor of Medicine and
Associate Director for Clinical Research, University
of Maryland Greenebaum Comprehensive Cancer Center, in an oral
session today at the 60th American Society of Hematology (ASH)
Annual Meeting in San Diego, CA, from 9:30AM a?? 11:00AM PT, in Grand Hall
B, Manchester Grand Hyatt.


This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181202005047/en/


NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting

Indoximod plus Chemotherapy in Acute Myeloid Leukemia (AML) (Graphic: Business Wire)
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930